Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections

Immunological Reviews

Volumn 170, Issue , 1999, Pages 151-172

  Berzofsky, Jay A ^a   Ahlers, Jeffrey D ^a   Derby, Michael A ^a   Pendleton, C David ^a   Arichi, Tutsumi ^a   Belyakov, Igor M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HEPATITIS C VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTATION; APOPTOSIS; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID SEQUENCE; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; EPITOPES; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNITY, MUCOSAL; MICE; MOLECULAR SEQUENCE DATA; PROTEIN ENGINEERING; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SYNTHETIC; VIRAL HEPATITIS VACCINES;

EID: 0032869689     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01336.x     Document Type: Review

References (172)

1. 1. Farci P, et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 1992;258:135-140.
2. 2. Hilleman MR. Six decades of vaccine development - a personal history. Nat Med 1998;4:507-514.
3. 3. LaRosa GJ. et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249:932-935.
4. 4. Kohler H, Goudsmit J, Nara P, Clonal dominance: cause for a limited and failing immune response to HIV-1 infection and vaccination. J Acquir Immune Defic Syndr Hum Retruvirol 1992;5:1158-1168.
5. 5. Korber B, et al. HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res Hum Retroviruses 1992;8:1461-1465.
6. 6. Takahashi H, et al. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988;85:3105-3109.
7. 7. Phillips RE, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition Nature 1991;354:453-459.
8. 8. Goulder PJR, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
9. 9. Borrow P, et al. Antiviral pressure exerted by HIV-1 -specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
10. 10. Sher A, et al. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol Rev 1992; 127:183-204.
11. 11. Hilleman MR. A simplified vaccinologists' vaccinology and the pursuit of a vaccine against AIDS. Vaccine 1998;16:778-793.
12. N2 switch is a critical step in the etiology of HIV infection, Immunol Today 1993;14:107-111.
13. 13. Clerici M, Berzofsky JA. Cellular immunity and cytokines in HIV infection. AIDS 1994;8 (Suppl I):S175-S182.
14. 14. Shearer GM. HIV induced immunopathogenesis. Immunity 1998;9:587-593.
15. 15. Golding H, et al. Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II β 1 domain I. Monoclonal antibodies against the gp41 -derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med 1988;167:914-923.
16. 16. Golding H, et al. Common epitope in human immunodeficiency virus (HIV) 1-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV 1 infected individuals. J Clin Invest 1989;83:1430-1435.
17. + cell depletion. Cell 1988;54:561-575.
18. 18. Mittler RS, Hoffmann MK, Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation. Science 1989;245:1380-1382.
19. 19. Wang ZQ, et al. Deletion of T lymphocytes in human CD4 transgenic mice induced by HIV-gp120 and gp120-specific antibodies from AIDS patients. Eur J Immunol 1994;24:1553-1557.
20. 20. Weinhold KJ, et al. Cellular anti gp120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet 1988;23:902-904.
21. 21. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239:476-481.
22. 22. Bokisch VA, Top FH, Russell PK, Dixon FJ, Muller-Eberhard HJ. The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med 1973;289:996-1000.
23. 23. Robinson WE Jr, Kawamura T, Lake D, Masuho Y, Mitchell WM, Hersh EM. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 1990;64:5301-5305.
24. 24. Homsy J, Meyer M, Tateno M, Clarkson S, Levy JA. The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science 1989;244:1357-1359.
25. 25. Takeda A. Robinson JE, Ho DD, Debouck C, Haigwood NL, Ennis FA. Distinction of human immunodeficiency virus type 1 neutralization and infection enhancement by human monoclonal antibodies to glycoprotein 120. J Clin Invest 1992;89:1952-1957.
26. 26. Rehermann B, et al. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol 1996;70:7092-7102.
27. 27. Koziel MJ, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339-3344.
28. 28. Koziel MJ, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-2321.
29. 29. Cease KB, et al. Helper T cell antigenic site identification in the AIDS virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987;84:4249-4253.
30. 30. Berzofsky JA, et al. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-Immune humans. Nature 1988;334:706-708.
31. 31. Clerici M, et al. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV seropositive individuals. Nature 1989;339:383-385.
32. 32. Hosmalin A, et al. Priming with helper T-cell epitope peptides enhances the antibody response to the envelope glycoprotein of HIV I in primates. J Immunol 1991;146:1667-1673.
33. 33. Palker TJ, et al. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J Immunol 1989;142:3612-3619.
34. 34. Hale PM, et al. T cell multideterminant regions in the human immunodeficiency virus envelope: toward overcoming the problem of major histocompatibility complex restriction. Int Immunol 1989;1:409-415.
35. 35. Berzofsky JA, et al. Construction of peptides encompassing multideterminant clusters of HIV envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. J Clin Invest 1991;88:876-884.
36. 36. Palker TJ, et al. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-1936.
37. 37. Rusche JR, et al. Antibodies that inhibit fusion of HIV infected cells bind a 24 amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
38. 38. Goudsmit J, et al. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 1988;85:4478-4482.
39. 39. Takahashi H, et al. A single amino acid interchange yields reciprocal CTL specificities for HIV gp160. Science 1989;246:118-121.
40. 40. Takahashi H, et al. Structural requirements for class-I MHC molecule-mediated antigen presentation and cytotoxic T-cell recognition of an immunodominant determinant of the HIV envelope protein. J Exp Med 1989;170:2023-2035.
41. 41. Shirai M, Pendleton CD, Berzofsky JA. Broad recognition of cytotoxic T-cell epitopes from the HIV-1 envelope protein with multiple class I histocompatibility molecules. J Immunol 1992;148:1657-1667.
42. 42. Bergmann CC, Tong L, Cua RV, Sensintaffar JL, Stohlman SA. Cytotoxic T cell repertoire selection: a single amino acid determines alternative class I restriction. J Immunol 1994;152:5603-5612.
43. 43. White WI, et al. Antibody and cytotoxic T lymphocyte responses to a single liposome-associated peptide antigen-Vaccine 1995;13:1111-1122.
44. 44. Okuda K, et al. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. J Mol Recognit 1993;6:101-109.
45. 45. Moore RI., Fox BS, Immunization of mice with human immunodeficiency virus glycoprotein gp160 peptide 315-329 induces both class I-and class II-restricted T cells: Not all T cells can respond to whole molecule stimulation, AIDS Res Hum Retroviruses 1993;9:51-59.
46. + cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. Proc Natl Acad Sci USA 1991;88:9448-9452.
47. 47. Porgador A, Staats HF, Faiola B, Gilboa E, Palker TJ. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. J Immunol 1997;158:834-841.
48. 48. Nehete PN, Casement KS, Arlinghaus RB, Sastry KJ. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120. Cell Immunol 1995;160:217-223.
49. 49. Clerici M, et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV seropositive individuals. J Immunol 1991;146:2214-2219.
50. 50. Achour A, et al. Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope. Vaccine 1993;11:699-701.
51. B peptide in an HLA-A11-immunized individual. AIDS Res Hum Retroviruses 1994;10:19-25.
52. 52. Alexander-Miller MA, Parker KC, Tsukui T, Pendleton CD, Coligan JE, Berzofsky JA. Molecular analysis of presentation by HLA-A2.1 of a promiscuously binding V3 loop peptide from the HIV-1 envelope protein to human CTL. Int Immunol 1996;8:641-649.
53. 53. Takahashi H, Germain RN, Moss B, Berzofsky JA. An immunodominant class I-restricted cytotoxic T lymphocyte determinant of human immunodeficiency virus type 1 induces CD4 class II-restricted help for itself. J Exp Med 1990;171:571-576.
54. + CTL in vivo with peptide vaccine constructs. J Immunol 1994;152:549-556.
55. 55. Takeshita T, et al. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule. J Immunol 1995;154:1973-1986.
56. 56. Javaherian K, et al. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990;250:1590-1593.
57. 57. Good MF, et al. Construction of a synthetic immunogen: use of a new T-helper epitope on malaria circumsporozoite protein. Science 1987;235:1059-1062.
58. 58. Golvano J, Lasarte JJ, Sarobe P, Gullón A, Prieto J. Borrás-Cuesta F. Polarity of immunogens: implications for vaccine design. Eur J Immunol 1990;20:2363-2366.
59. 59. Lasarte JJ, Sarobe P, Gullón A, Prieto J, Borrás-Cuesta F. Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct. Cell Immunol 1992;141:211-218.
60. 60. Sarobe P, et al. Induction of neutralizing antibodies against human immunodeficiency virus type 1 using synthetic peptide constructs containing an immunodominant T-helper cell determinant from vpr. J AIDS 1994;7:635-640.
61. 61. Ahlers JD, Pendleton CD, Dunlop N, Minassian A, Nara PL, Berzofsky JA. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations . J Immunol 1993;150:5647-5665.
62. 62. Mitchison NA. The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1971;1:18.
63. 63. Singer A, Hodes RJ, Mechanisms of T cell-B cell interaction. Annu Rev Immunol 1983;1:211-241.
64. 64. Robbins JE, Schneerson R. Polysaccharide-protein conjugates: a new generation of vaccines. J Infect Dis 1990;161:821-832.
65. 65. Widmann C, Romero P, Maryanski JL, Corradin G, Valmori D. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J Immunol Methods 1992;155:95-99.
66. 66. Shirai M, et al. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J Infect Dis 1996;173:24-31.
67. 67. Lanzavecchia A. Antigen-specific interaction between T cells and B cells. Nature 1985;314:537-539.
68. 68. Ozaki S, Berzofsky JA. Antibody conjugates mimic specific B cell presentation of antigen: Relationship between T and B cell specificity. J Immunol 1987;138:4133-4142.
69. 69. Berzofsky JA, Berkower IJ. Immunogenicity and antigen structure. In: Paul WE, ed. Fundamental immunology. 4th ed. Philadelphia: Lippincott-Raven: 1999. p, 651-699.
70. 70. Gill RG, Lafferty KJ. A quantitative analysis of lymphokine release from activated T cells: Evidence for a novel form of T-T collaboration in vitro. J Immunol 1989;143:4009-4014.
71. 71. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992;10:333-358.
72. 72. Guerder S, Matzinger P. A fail-safe mechanism for maintaining self-tolerance. J Exp Med 1992;176:553-564.
73. + cytotoxic T lymphocytes in the absence of exogenous help. J Exp Med 1993;177:1791-1796.
74. + T-helper and a T-killer cell. Nature 1998;393:474-478.
75. 75. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP. Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998;393:478-480.
76. 76. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM, T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998;393:480-483.
77. 77. Myers G, Josephs SF, Berzofsky JA, Rabson AB, Smith TF, Wong-Staal F. Human retroviruses and AIDS 1989. New Mexico: Los Alamos National Laboratory; 1989.
78. 78. Ahlers JD, Dunlop N, Pendleton CD, Newman M, Nara PL, Berzofsky JA. Candidate HIV type1 multideterminant cluster peptide P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization, AIDS Res Hum Retroviruses 1996;12:259-272.
79. 79. Pinto L, et al. HIV-specific immunity following immunization with HIV synthetic envelope peptide in asymptomatic HIV-infected patients, AIDS (In press).
80. 80. Hart MK, et al. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys. J Immunol 1990;145:2677-2685.
81. 81. Haynes BF, et al. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. J Immunol 1993;151:1646-1653.
82. 82. Bartlett JA, et al. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. AIDS 1998;12:1291-1300.
83. 83. Cease KB. Peptide component vaccine engineering: targeting the AIDS virus. Intern Rev Immunol 1990;7:85-107.
84. 84. Cease KB, Berzofsky JA, Towards a vaccine for AIDS: the emergence of immunobiology-based vaccine development. Annu Rev Immunol 1994;12:923-989.
85. 85. Oscherwitz J, Gotch FM, Cease KB, Berzofsky JA. New insights and approaches regarding B and T cell epitopes in HIV vaccine design. AIDS 1999;13 (Suppl A):S163-S174.
86. 86. Berzofsky JA. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. Ann N Y Acad Sci 1993;690:256-264.
87. 87. Berzofsky JA. Designing peptide vaccines to broaden recognition and enhance potency. Ann N Y Acad Sci 1995;754:161-168.
88. 88. Berzofsky JA, Berkower IJ. Novel approaches to peptide and engineered protein vaccines for HIV using defined epitopes: advances in 1994-95. AIDS 1995;9(Suppl A):S143-S157.
89. 89. Boehncke W-H, et al. The importance of dominant negative effects of amino acids side chain substitution in peptide-MHC molecule interactions and T cell recognition. J Immunol 1993;150:331-341.
90. 90. Ratner L, et al. Complete nucleotide sequence of the AIDS virus HTLV-III. Nature 1985;313:277-284.
91. 91. Schwartz RH. T-lymphocyte recognition of antigen in association with gene products of the major histocompatibility complex. Annu Rev Immunol 1985;3:237-261.
92. 92. Ahlers JD, Takeshita T, Pendleton CD, Berzofsky JA. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 1997;94:10856-10861.
93. 93. Shirai M, et al. An epitope in hepatitis C virus core region recognized by cytotoxic T cells in mice and humans. J Virol 1994;68:3334-3342.
94. 94. Battegay M, et al. Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules. J Virol 1995;69:2462-2470.
95. 95. Shirai M, et al. CTL responses of HLA-A2.1 -transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA A2.1. J Immunol 1995;154:2733-2742.
96. 96. Falk K, Rötzschke O, Stevanovic S, Jung G, Rammensee H-G. Allele-specific motifs revealed by sequencing of self peptides eluted from MHC molecules. Nature 1991;351:290-296.
97. 97. Hunt DF, et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992;255:1261-1263.
98. 98. Ruppert J, Sidney J, Celis F, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993;74:929-937.
99. 99. Sarobe P. et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 1998;102:1239-1248.
100. 100. Ahlers JD, Dunlop N, Alling DW, Nara PL, Berzofsky JA. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: GM-CSF and TNFα synergize with IL-12 to enhance induction of CTL. J Immunol 1997;158:3947-3958.
101. 101. Takahashi H, et al. Induction of broadly cross-reactive cytotoxic T cells recognizing an HIV-1 envelope determinant. Science 1992;255:333-336.
102. 102. Hosmalin A, et al. An epitope in HIV-1 reverse transcriptase recognized by both mouse and human CTL. Proc Natl Acad Sci USA 1990;87:2344-2348.
103. 103. Leggatt GR, Hosmalin A, Pendleton CD, Kumar A, Huffman S, Berzofsky JA. The importance of pairwise interactions between peptide residues in the delineation of T cell receptor specificity. J Immunol 1998;161:4728-4735.
104. 104. Pogue RR, Eron J, Frelinger JA, Matsui M. Amino-terminal alteration of the HLA-A0201 -restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. Proc Natl Acad Sci USA 1995;92;8166-8170.
105. 105. Parkhurst MR, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 -binding residues. J Immunol 1996;157:2539-2548.
106. 106. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327.
107. 107. Saito T, et al. Plasmid DNA based immunization for hepatitis C virus structural proteins, immune responses in mice. Gastroenterology 1997;112:1321-1330.
108. 108. Earl PL, Hugin AW, Moss B. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J Viral 1990;64:2448-2451.
109. 109. Alexander-Miller MA, Leggatt GR, Berzofsky JA, Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc Natl Acad Sci USA 1996;93:4102-4107.
110. 110. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998;187:1647-1657.
111. 111. Zeh III HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 1999;162:989-994.
112. 112. Yee C, Savage PA, Lee PP, Davis MM, Greenberg PD. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-mhc tetramers. J Immunol 1999;162:2227-2234.
113. 113. Alexander-Miller MA, Leggatt GR, Sarin A, Berzofsky JA. Role of antigen, CD8, and Cytotoxic T Lymphocyte avidity in high dose antigen induction of apoptosis of effector CTL. J Exp Med 1996;184:485-492.
114. 114. Alexander-Miller MA, Derby MA, Sarin A, Henkart PA, Berzofsky JA. Supra-optimal peptide/MHC causes a decrease in Bcl-2 and allows TNF-α receptor II-mediated apoptosis of CTL. J Exp Med 1998;188:1391-1399.
115. 115. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995;377:348-351.
116. 116. Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991;353:858-861.
117. 117. Critchfield JM, Zún̄iga-Pflücker JC, Lenardo MJ. Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cell Immunol 1995;160:71-78.
118. 118. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
119. 119. Gallimore A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibilily complex class 1-peptide complexes. J Exp Med 1998;187:1383-1393.
120. 120. Kawamura H, Rosenberg SA, Berzofsky JA. Immunization with antigen and interleukin-2 in vivo overcomes Ir genetic low responsiveness. J Exp Med 1985;162:381-386.
121. 121. Good MF, et al. Recombinant human interleukin-2 (IL-2) overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biological activity of IL-2. J Immunol 1988;141:972-977.
122. 122. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46:111-147.
123. 123. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
124. 124. Pfeiffer C, Murray J, Madri J, Bottomly K, Selective activarion of Th1-and Th2-like cells in vivo - response to human collagen IV. Immunol Rev 1991;123:65-84.
125. H1 cell development. Science 1996;271:984-987.
126. 126. Xiang Z, Ertl HCJ. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995;2:129-135.
127. 127. Iwasaki A, Stiernholm BJN, Chan AK, Berinstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997;158:4591-4601.
128. 128. Kim JJ, et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997;158:816-826.
129. 129. Neutra MR. HIV transmission and immune protection at mucosal surfaces. Adv Exp Med Biol 1998;452:169-175.
130. 130. Veazey RS, Lackner AA. The gastrointestinal tract and the pathogenesis of AIDS. AIDS 1998;12: S35-S42.
131. 131. Bergmeier LA, et al. Antibody-secreting cells specific for simian immunodeficiency virus antigens in lymphoid and mucosal tissues of immunized macaques. AIDS 1998;12:1139-1147.
132. 132. Heeney JL, et al. β-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 1998;95:10803-10808.
133. 133. McGhee JR, Mestecky J. Dertzbaugh MT, Eldridge JH, Hirasawa M, Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992;10:75-88.
134. 134. Klavinskis LS, et al. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTI. in the genito-rectal mucosa and draining lymph nodes. J Immunol 1996;157:2521-2527.
135. 135. Kelsall BL, Strober W. Peyer's patch dendritic cells and the induction of mucosal immune responses. Res Immunol 1997;148:490-498.
136. 136. Belyakov IM, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Natl Acad Sci USA 1998;95:1709-1714.
137. 137. Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 1995;63:1617-1623.
138. + cytotoxic T lymphocytes for resistance to mucosal-viral transmission in mice and enhancement of resistance by local administration of IL-12. J Clin Invest 1998;102:2072-2081.
139. 139. Bennink J, Effros RB, Doherty PC. Influenzal pneumonia: early appearance of cross-reactive T cells in lungs of mice primed with heterologous type A viruses. Immunology 1978;35:503-509.
140. 140. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization. J Exp Med 1996;184:1879-1890.
141. 141. Lohman BL, Miller CJ, McChesney MB. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. J Immunol 1995;155:5855-5860.
142. 142. Murphey-Corb M, et al. Selective induction of protective MHC class I restricted CTL in the intestinal lamina propria of rhesus monkeys by transient SIV infection of the colonic mucosa. J Immunol 1999;162:540-549.
143. 143. Cranage MP, et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997;229:143-154.
144. 144. Lehner T, et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996;2:767-775.
145. 145. Putkonen P, Makitalo B, Bottiger D, Biberfeld G, Thorstensson R. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J Virol 1997;71:4981-4984.
146. 146. Miller CJ. et al. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol 1997;71:1911-1921.
147. 147. Quesada-Rolander M, et al. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res Hum Retroviruses 1996;12:993-999.
148. 148. Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, Small PA Jr. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol 1996;70:6418-6424.
149. 149. Wang B, et al. Mucosal immunization with a DNA vaccine induces immune responses against HIV-I at a mucosal site. Vaccine 1997;15:821-825.
150. 150. Taylor PM, Askonas BA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology 1986;58:417-420.
151. 151. Epstein SL, Lo C-Y, Misplon JA. Bennink JR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998;160:322-327.
152. 152. Kulkarni AB, et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol 1995;69:1261-1264.
153. 153. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 1991;252:1662.
154. 154. Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci USA 1996;93:11349-11353.
155. 155. Tartaglia J, et al. NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992;188:217-232.
156. 156. Mayr A, Stickl H, Muller HK. Danner K, Singer H, [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol [B] 1978;167:375-390.
157. 157. Mayr A, Hochstein-Mintzel V, Stickl H. Abstammung, eigenschaften and verwendung des attenuierten vaccinia-stammes MVA. Infection 1975;3:6-14.
158. 158. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 1991;72:1031-1038.
159. 159. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci USA 1992;89:10847-10851.
160. 160. Belyakov IM, et al. Induction of mucosal CTL response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing HIV 89.6 envelope protein, J Virol 1998;72:8264-8272.
161. 161. Seth A, et al. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in Rhesus monkeys detected by an major histocompatibility complex class I/peptide tetramer. Proc Natl Acad Sci USA 1998;95:10112-10116.
162. 162. Hirsch VM, et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996;70:3741-3752.
163. 163. Hanke T, et al. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. J Gen Virol 1998;79:83-90.
164. 164. Hanke T, et al. Enhancement of MHC class I-restricted peptide specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 1998;16:439-445.
165. 165. Hanke T, Schneider J, Gilbert SC, Hill AVS, McMichael A, DNA multi-CTL epirope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998;16:426-435.
166. 166. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997;238:198-211.
167. 167. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B, A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994;12:1032-1040.
168. 168. Rooney JF, Wohlenberg C, Cremer KJ, Moss B, Notkins AL. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 1988;62:1530-1534.
169. 169. Cooney EL, et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991;337:567-572.
170. 170. Belyakov TM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 1999;96:4512-4517.
171. + cytotoxic T lymphocytes by free antigenic peptide: a self-veto mechanism? J Exp Med 1996;183:879-889.
172. 2+ independent T cell-mediated cytotoxicity. J Exp Med 1993;177:195-200.